A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination with VS-6766 and Defactinib in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Metastatic Adenocarcinoma Of The Pancreas
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    To participate in the study the following conditions must be met:
    1. 1) Metastatic pancreatic ductal adenocarcinoma (PDAC) that has been confirmed through tissue or cell tests.
    2. 2) A subject has pancreatic cancer that has spread to other parts of the body and they haven't received any medicine for it before, and they are eligible for a standard treatment called gemcitabine and nab-paclitaxel as their first treatment.
    3. 3) Must agree to give samples of their tissue and blood for research.

You may not be eligible for this study if the following are true:

  • You will not be able to participate in the study if you have had:
    1. 1) Pancreatic neuroendocrine tumors (PNET), islet cell tumors, mucinous cystic, squamous or adenosquamous histologies.
    2. 2) Prior or concomitant treatment for metastatic pancreatic ductal adenocarcinoma.
    3. 3) Presence of symptomatic ascites (having excess fluid in the abdomen that is causing uncomfortable symptoms).



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.